Literature DB >> 16448150

Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.

Anna F A Peacock1, Abraha Habtemariam, Rafael Fernández, Victoria Walland, Francesca P A Fabbiani, Simon Parsons, Rhona E Aird, Duncan I Jodrell, Peter J Sadler.   

Abstract

The Os(II) arene ethylenediamine (en) complexes [(eta(6)-biphenyl)Os(en)Cl][Z], Z = BPh(4) (4) and BF(4) (5), are inactive toward A2780 ovarian cancer cells despite 4 being isostructural with an active Ru(II) analogue, 4R. Hydrolysis of 5 occurred 40 times more slowly than 4R. The aqua adduct 5A has a low pK(a) (6.3) compared to that of [(eta(6)-biphenyl)Ru(en)(OH(2))](2+) (7.7) and is therefore largely in the hydroxo form at physiological pH. The rate and extent of reaction of 5 with 9-ethylguanine were also less than those of 4R. We replaced the neutral en ligand by anionic acetylacetonate (acac). The complexes [(eta(6)-arene)Os(acac)Cl], arene = biphenyl (6), benzene (7), and p-cymene (8), adopt piano-stool structures similar to those of the Ru(II) analogues and form weak dimers through intermolecular (arene)C-H...O(acac) H-bonds. Remarkably, these Os(II) acac complexes undergo rapid hydrolysis to produce not only the aqua adduct, [(eta(6)-arene)Os(acac)(OH(2))](+), but also the hydroxo-bridged dimer, [(eta(6)-arene)Os(mu(2)-OH)(3)Os(eta(6)-arene)](+). The pK(a) values for the aqua adducts 6A, 7A, and 8A (7.1, 7.3, and 7.6, respectively) are lower than that for [(eta(6)-p-cymene)Ru(acac)(OH(2))](+) (9.4). Complex 8A rapidly forms adducts with 9-ethylguanine and adenosine, but not with cytidine or thymidine. Despite their reactivity toward nucleobases, complexes 6-8 were inactive toward A549 lung cancer cells. This is attributable to rapid hydrolysis and formation of unreactive hydroxo-bridged dimers which, surprisingly, were the only species present in aqueous solution at biologically relevant concentrations. Hence, the choice of chelating ligand in Os(II) (and Ru(II)) arene complexes can have a dramatic effect on hydrolysis behavior and nucleobase binding and provides a means of tuning the reactivity and the potential for discovery of anticancer complexes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16448150     DOI: 10.1021/ja055886r

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  38 in total

Review 1.  Redox activation of metal-based prodrugs as a strategy for drug delivery.

Authors:  Nora Graf; Stephen J Lippard
Journal:  Adv Drug Deliv Rev       Date:  2012-01-25       Impact factor: 15.470

2.  Similar biological activities of two isostructural ruthenium and osmium complexes.

Authors:  Jasna Maksimoska; Douglas S Williams; G Ekin Atilla-Gokcumen; Keiran S M Smalley; Patrick J Carroll; Richard D Webster; Panagis Filippakopoulos; Stefan Knapp; Meenhard Herlyn; Eric Meggers
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

3.  Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.

Authors:  Hana Kostrhunova; Jaroslav Malina; Amanda J Pickard; Jana Stepankova; Marie Vojtiskova; Jana Kasparkova; Tereza Muchova; Matthew L Rohlfing; Ulrich Bierbach; Viktor Brabec
Journal:  Mol Pharm       Date:  2011-08-17       Impact factor: 4.939

4.  Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways.

Authors:  Kogularamanan Suntharalingam; Timothy C Johnstone; Peter M Bruno; Wei Lin; Michael T Hemann; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2013-09-16       Impact factor: 15.419

5.  Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes.

Authors:  Zuzana Sochorová Vokáčová; Iztok Turel; Jaroslav V Burda
Journal:  J Mol Model       Date:  2018-03-20       Impact factor: 1.810

6.  Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy.

Authors:  Lukas K Filak; Gerhard Mühlgassner; Michael A Jakupec; Petra Heffeter; Walter Berger; Vladimir B Arion; Bernhard K Keppler
Journal:  J Biol Inorg Chem       Date:  2010-04-06       Impact factor: 3.358

7.  cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.

Authors:  Gabriel E Büchel; Susanne Kossatz; Ahmad Sadique; Peter Rapta; Michal Zalibera; Lukas Bucinsky; Stanislav Komorovsky; Joshua Telser; Jörg Eppinger; Thomas Reiner; Vladimir B Arion
Journal:  Dalton Trans       Date:  2017-09-12       Impact factor: 4.390

Review 8.  Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.

Authors:  Sabine H van Rijt; Peter J Sadler
Journal:  Drug Discov Today       Date:  2009-09-24       Impact factor: 7.851

9.  Rhodium(III) and iridium(III) complexes with 1,2-naphthoquinone-1-oximate as a bidentate ligand: synthesis, structure, and biological activity.

Authors:  Stefan Wirth; Christoph J Rohbogner; Marcin Cieslak; Julia Kazmierczak-Baranska; Stefan Donevski; Barbara Nawrot; Ingo-Peter Lorenz
Journal:  J Biol Inorg Chem       Date:  2009-12-19       Impact factor: 3.358

Review 10.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.